What do systematic reviews say?

Chemotherapy vs chemotherapy alone

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Very low

Chemotherapy vs no chemotherapy

The review found no eligible studies for this question.

• Management of people with intermediate‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Delayed chemotherapy vs immediate chemotherapy

• Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 161 participants
  Very low

Platinum‐containing chemotherapy vs chemotherapy without platinum

The review found no eligible studies for this question.

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

ATRA in addition to chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML)… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Adjuvant chemotherapy vs no chemotherapy

The review found no eligible studies for this question.

• Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Low

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bevacizumab plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Taxane‐containing chemotherapy vs any chemotherapy without taxane

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 7 participants
  Low

Chemotherapy (any regimen; added to, or compared with, locoregional treatment) vs Locoregional treatment and/or an alternative chemotherapy regimen

The review found no eligible studies for this question.

• Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy 2021 · Cochrane All outcomes
  Quality of life was a planned (protocol) outcome but no included trial provided usable quality-of-life data; the protocol was modified to report only survival/response outcomes.
  0 studies
  No studies found

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

TG4010 added to chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 608 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 146 participants
  Low

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 315 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1340 participants
  Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 486 participants
  Low